Volume | 3,586 |
|
|||||
News | - | ||||||
Day High | 0.000001 | Low High |
|||||
Day Low | 0.000001 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Taxus Cardium Pharmaceuticals Group Inc (CE) | CRXM | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.000001 | 0.000001 | 0.000001 | 0.000001 | 0.0001 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2 | 3,586 | $ 0.000001 | $ 0.0032 | - | 0.000001 - 0.0001 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:26:35 | 586 | $ 0.000001 | USD |
Taxus Cardium Pharmaceuticals Group Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 64.93 | 64.93M | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Taxus Cardium Pharmaceut... (CE) News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRXM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.000001 | 0.000001 | 0.000001 | 0.000001 | 2,000 | 0.00 | 0.0% |
1 Month | 0.000001 | 0.0001 | 0.000001 | 0.0000188 | 663 | 0.00 | 0.0% |
3 Months | 0.000001 | 0.0001 | 0.000001 | 0.0000188 | 663 | 0.00 | 0.0% |
6 Months | 0.000001 | 0.0001 | 0.000001 | 0.0000076 | 1,430 | 0.00 | 0.0% |
1 Year | 0.0001 | 0.0001 | 0.000001 | 0.0000347 | 15,734 | -0.0001 | -99.0% |
3 Years | 0.0375 | 0.0755 | 0.000001 | 0.0470998 | 516,219 | -0.0375 | -100.0% |
5 Years | 0.062 | 0.19 | 0.000001 | 0.0547776 | 248,175 | -0.062 | -100.0% |
Taxus Cardium Pharmaceut... (CE) Description
Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen(R) topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx(R) is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. |